Baxter announces Artiss approval

A new product that uses slow-setting fibrin sealant technology for use in the treatment of skin grafts and burns has been given approval by the US Food and Drug Administration (FDA), it has emerged.

Baxter has announced that it has been able to secure FDA approval of its Artiss sealant which adds to the company’s growing BioSurgery range of products.

It is reported that Artiss has improved on existing skin sealant technology, which sets in around five to ten seconds, by offering a solution that sets in approximately 60 seconds – allowing the graft to be manipulated more carefully and slowly.

Commenting on the news, Baxter’s BioSurgery general manager Ron Lloyd said he welcomed the approval which showed Artiss was “a safe and effective alternative to staples”.

“This is another example of Baxter’s scientific leadership in specialty biologic products, serving needs of patients and physicians,” he added.

In December, the group announced it had won FDA approval for its Gelfoam Plus treatment which is used to control bleeding for patients undergoing surgical procedures.